Teva's generic Advair may sit 'til 2018

Share this article:

September FDA draft guidance looked like it could make it easier for generics of GlaxoSmithKline's asthma/COPD medication Advair to hit the market. The issue at the time was that the guidance indicated generics rivals could bypass human trials in their pursuit of regulatory approval.

The guidance, however, does not address a mechanical challenge, which is the complexity of the inhaler itself, for which GSK has a patent until 2016.

The new news: Teva announced on Tuesday that it does not expect to drop its generic Advair into the US market for at least another five years, reports Reuters, noting that this delay insulates GSK's $8 billion-a-year money maker for a while longer. It also buys more time for GSK COPD drug Breo Ellipta—Ellipta is the inhaler—to gain traction. The FDA approved Breo Ellipta in May.

Share this article:

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.